Potent antibody drug conjugates for cancer therapy

Reichert, 2005, Monoclonal antibody successes in the clinic, Nat Biotechnol, 23, 1073, 10.1038/nbt0905-1073 Reichert, 2007, Development trends for monoclonal antibody cancer therapeutics, Nat Rev Drug Discov, 6, 349, 10.1038/nrd2241 Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc Chem Res, 41, 98, 10.1021/ar700108g Damle, 2004, Tumour-targeted chemotherapy with immunoconjugates of calicheamicin, Expert Opin Biol Ther, 4, 1445, 10.1517/14712598.4.9.1445 Kovtun, 2007, Cell killing by antibody-drug conjugates, Cancer Lett, 255, 232, 10.1016/j.canlet.2007.04.010 Wu, 2005, Arming antibodies: prospects and challenges for immunoconjugates, Nat Biotechnol, 23, 1137, 10.1038/nbt1141 Pietersz, 1994, Chemoimmunoconjugates for the treatment of cancer, Adv Immunol, 56, 301, 10.1016/S0065-2776(08)60455-1 Trail, 2003, Monoclonal antibody drug immunoconjugates for targeted treatment of cancer, Cancer Immunol Immunother, 52, 328, 10.1007/s00262-002-0352-9 Trail, 1993, Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates, Science, 261, 212, 10.1126/science.8327892 Saleh, 2000, Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors, J Clin Oncol, 18, 2282, 10.1200/JCO.2000.18.11.2282 Tolcher, 1999, Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, J Clin Oncol, 17, 478, 10.1200/JCO.1999.17.2.478 Damle, 2003, Antibody-targeted chemotherapy with immunoconjugates of calicheamicin, Curr Opin Pharmacol, 3, 386, 10.1016/S1471-4892(03)00083-3 Boghaert, 2008, Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 mul) blood samples, Cancer Chemother Pharmacol, 61, 1027, 10.1007/s00280-007-0560-2 Boghaert, 2004, Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl γ calicheamicin dimethyl hydrazide targets LewisY and eliminates LewisY-positive human carcinoma cells and xenografts, Clin Cancer Res, 10, 4538, 10.1158/1078-0432.CCR-04-0037 Boghaert, 2008, The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin, Int J Oncol, 32, 221 Hamann, 2005, An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance, Bioconjug Chem, 16, 346, 10.1021/bc049795f Trail, 1997, Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates, Cancer Res, 57, 100 DiJoseph, 2004, Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies, Blood, 103, 1807, 10.1182/blood-2003-07-2466 DiJoseph, 2004, Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma, Clin Cancer Res, 10, 8620, 10.1158/1078-0432.CCR-04-1134 DiJoseph, 2005, Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22, Cancer Immunol Immunother, 54, 11, 10.1007/s00262-004-0572-2 Bross, 2001, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin Cancer Res, 7, 1490 Hamann, 2002, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia, Bioconjug Chem, 13, 47, 10.1021/bc010021y Larson, 2005, Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence, Cancer, 104, 1442, 10.1002/cncr.21326 Boghaert, 2006, Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy, Int J Oncol, 28, 675 Jedema, 2004, Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity, Leukemia, 18, 316, 10.1038/sj.leu.2403205 Doronina, 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity, Bioconjug Chem, 17, 114, 10.1021/bc0502917 Doronina, 2003, Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat Biotechnol, 21, 778, 10.1038/nbt832 Thorpe, 1988, Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages, Cancer Res, 48, 6396 Thorpe, 1987, New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo, Cancer Res, 47, 5924 Widdison, 2006, Semisynthetic maytansine analogues for the targeted treatment of cancer, J Med Chem, 49, 4392, 10.1021/jm060319f Kovtun, 2006, Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen, Cancer Res, 66, 3214, 10.1158/0008-5472.CAN-05-3973 Liu, 1996, Eradication of large colon tumor xenografts by targeted delivery of maytansinoids, Proc Natl Acad Sci U S A, 93, 8618, 10.1073/pnas.93.16.8618 Chen, 2007, αv integrin-targeted immunoconjugates regress established human tumors in xenograft models, Clin Cancer Res, 13, 3689, 10.1158/1078-0432.CCR-07-0026 Aboukameel, 2007, Superior anti-tumor activity of the CD19-directed immunotoxin. SAR3419 to rituximab in non-Hodgkin's xenograft animal models: preclinical evaluation, Blood, 110, 10.1182/blood.V110.11.2339.2339 Henry, 2004, A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer, Cancer Res, 64, 7995, 10.1158/0008-5472.CAN-04-1722 Legrand, 2007, An open label, dose escalation study of AVE9633 administered as a single agent by intravenous (IV) infusion weekly for 2 weeks in 4-week cycle to patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML), Blood, 110, 10.1182/blood.V110.11.1850.1850 Polson, 2009, Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and Linker-Drug Selection, Cancer Res, 69, 2358, 10.1158/0008-5472.CAN-08-2250 Tassone, 2004, Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells, Blood, 104, 3688, 10.1182/blood-2004-03-0963 Tassone, 2004, In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells, Cancer Res, 64, 4629, 10.1158/0008-5472.CAN-04-0142 Dubowchik, 1998, Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin, Bioorg Med Chem Lett, 8, 3341, 10.1016/S0960-894X(98)00609-X Dubowchik, 1998, Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin, Bioorg Med Chem Lett, 8, 3347, 10.1016/S0960-894X(98)00610-6 Walker, 2002, Synthesis of an immunoconjugate of camptothecin, Bioorg Med Chem Lett, 12, 217, 10.1016/S0960-894X(01)00707-7 Walker, 2004, Monoclonal antibody mediated intracellular targeting of tallysomycin S(10b), Bioorg Med Chem Lett, 14, 4323, 10.1016/j.bmcl.2004.05.089 Francisco, 2003, cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity, Blood, 102, 1458, 10.1182/blood-2003-01-0039 Sanderson, 2005, In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate, Clin Cancer Res, 11, 843, 10.1158/1078-0432.843.11.2 Ryan, 2007, Antibody targeting of B-cell maturation antigen on malignant plasma cells, Mol Cancer Ther, 6, 3009, 10.1158/1535-7163.MCT-07-0464 Benjamin D, et al.: Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 2007: p. Abstract B60. Law, 2004, Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates, Clin Cancer Res, 10, 7842, 10.1158/1078-0432.CCR-04-1028 Law, 2006, Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates, Cancer Res, 66, 2328, 10.1158/0008-5472.CAN-05-2883 Bhaskar, 2003, E-selectin up-regulation allows for targeted drug delivery in prostate cancer, Cancer Res, 63, 6387 Mao, 2004, EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer, Cancer Res, 64, 781, 10.1158/0008-5472.CAN-03-1047 Tse, 2006, CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma, Clin Cancer Res, 12, 1373, 10.1158/1078-0432.CCR-05-2018 Chen, 2007, Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models, Cancer Res, 67, 4924, 10.1158/0008-5472.CAN-06-4512 Ma, 2006, Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen, Clin Cancer Res, 12, 2591, 10.1158/1078-0432.CCR-05-2107 Afar, 2004, Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer, Mol Cancer Ther, 3, 921, 10.1158/1535-7163.921.3.8 Erickson, 2006, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing, Cancer Res, 66, 4426, 10.1158/0008-5472.CAN-05-4489 Alley, 2008, Contribution of linker stability to the activities of anticancer immunoconjugates, Bioconjug Chem, 19, 759, 10.1021/bc7004329 King, 2002, Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains, J Med Chem, 45, 4336, 10.1021/jm020149g Hollander, 2008, Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates, Bioconjug Chem, 19, 358, 10.1021/bc700321z Hamblett, 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate, Clin Cancer Res, 10, 7063, 10.1158/1078-0432.CCR-04-0789 Younes A., et al.: A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study. 7th International Symposium on Hodgkin Lymphoma 2007: p. Abstract PO99bis. Younes A., et al.: Objective responses in a Phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. American Society of Clinical Oncology 2008: p. Abstract 8526. McDonagh, 2006, Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment, Protein Eng Des Sel, 19, 299, 10.1093/protein/gzl013 Sun, 2005, Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides, Bioconjug Chem, 16, 1282, 10.1021/bc050201y Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat Biotechnol, 10.1038/nbt.1480 Beeram, 2007, A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC), J Clin Oncol, 25 Krop IE, et al.: A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer. 30th Annual San Antonio Breast Cancer Symposium 2007: p. Abstract 310. Pollack, 2007, Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB, Cancer Chemother Pharmacol, 60, 423, 10.1007/s00280-007-0490-z Sznol M., et al.: Phase I pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics 2007: p. Abstract B47. Sievers, 2001, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse, Expert Opin Biol Ther, 1, 893, 10.1517/14712598.1.5.893 Dijoseph, 2007, Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia, Leukemia, 21, 2240, 10.1038/sj.leu.2404866 Mita, 2007, A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors, J Clin Oncol, 25 Chanan-Khan, 2007, Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma, Blood, 110 McCann, 2007, Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma, J Clin Oncol, 25